XELOX与FOLFOX6辅助化疗方案在标准周期下治疗直肠癌术后患者的临床比较  

Clinical Comparison of XELOX and FOLFOX6 Adjuvant Chemotherapy in Rectal Cancer Patients under the Standardized Treatment Cycle

作　　者：高炳乾 李继林 赖浩[1] 冯雁[1] 林源[1] GAO Bingqian;LI Jilin;LAI Hao(Department of Gastrointestinal Surgery,Affiliated Tumor Hospital of Guangxi Medical University,Guangxi Medical University Graduate School,Nanning,530021,China)

机构地区：[1]广西医科大学附属肿瘤医院胃肠外科,广西医科大学研究生院,530021

出　　处：《航空航天医学杂志》2018年第12期1435-1438,共4页Journal of Aerospace medicine

基　　金：结直肠癌转移浸润的生物诱导机制和临床诊疗模式转化的研究(基金编号:桂科AB16380202)

摘　　要：目的比较直肠癌术后患者在标准周期下完成奥沙利铂联合卡培他滨(XELOX方案)与奥沙利铂联合5-氟尿嘧啶/亚叶酸钙(FOLFOX6方案)两种辅助化疗方案的预后、不良反应和生活质量的差异。方法分析2013年10月-2017年10月收治的71例Ⅱ-Ⅲ期直肠癌术后患者,其中XELOX组38例,FOLFOX6组33例,在完成标准化疗周期后,比较两组的生存率、不良反应以及生活质量。结果术后1、3年无病生存率,XELOX组分别为97. 3%、89. 4%,FOLFOX6组分别为96. 9%、87. 8%,两组差异无统计学意义(P=0. 260);术后1、3年总生存率,XELOX组分别为92. 1%、89. 4%,FOLFOX6组分别为87. 8%、84. 8%,两组差异无统计学意义(P=0. 255)。XELOX组手足综合征的发生率明显高于FOLFOX6组(P=0. 034),FOLFOX6组白细胞减少、血小板和肝功能异常的发生率明显高于XELOX组(P <0. 05),恶心呕吐两组差异无统计学意义(P> 0. 05)。XELOX组在情感状况的得分优于FOLFOX6组(P <0. 05)。生理状态,社会家庭状况,功能状况,两组患者的得分均无统计学意义(P> 0. 05)。结论两种化疗方案对直肠癌术后患者预后的影响无显著性差异; XELOX治疗方案可降低白细胞减少、血小板和肝功能异常的发生率,但增加了手足综合征的发生率; XELOX组患者生活质量略高。Objective To compare the prognosis,adverse reactions and quality of life of oxaliplatin combined with capecitabine( XELOX) and oxaliplatin combined with 5-fluorouracil/calcium folinate( FOLFOX6) adjuvant chemotherapy regimens under the standard cycle in rectal cancer patients after operation. Methods 71 patients with stage Ⅱ-Ⅲ rectal cancer who underwent gastrointestinal surgery in Cancer Hospital Affiliated to Guangxi Medical University from October 2013 to October 2017 were retrospectively analyzed. Among them,38 were treated with XELOX and 33 were treated with FOLFOX6. After completing the standardized treatment cycle,the survival rate,adverse reactions and quality of life of the two groups were compared. Results The disease-free survival rates of one year and three years after operation were 97. 3% and 89. 4% in XELOX group,96. 9% and 87. 8% in FOLFOX 6 group,respectively. There was no significant difference between the two groups( P = 0. 260); the overall survival rates of one year and three years after operation were 92. 1% and 89. 4% in XELOX group,87. 8% and 84. 8% in FOLFOX 6 group,respectively. There was no significant difference between the two groups( P = 0. 255). The incidence of hand-foot syndrome in XELOX group was significantly higher than that in FOLFOX6 group( P = 0. 034). The incidence of leukopenia,platelet and liver dysfunction in FOLFOX6 group was significantly higher than that in XELOX group( P <0. 05). There was no significant difference in nausea and vomiting between the two groups( P > 0. 05). The score of emotional status in group XELOX was better than that in group FOLFOX6( P < 0. 05). There was no significant difference in the scores of physiological status,social and family status and functional status between the two groups( P > 0. 05). Conclusions There was no significant difference between the two chemotherapy regimens on the prognosis of rectal cancer patients after operation; XELOX regimen can reduce the incidence of leukopenia,platelet and liver dysfunction,but increase the

关 键 词：直肠癌 辅助化疗 5-氟尿嘧啶 卡培他滨 生存率 不良反应 

分 类 号：R735.3[医药卫生—肿瘤]